ResearcherPeking UniversityActive in the last 2 years
Tianyan Zhou
Matched on ORCID iD 0000-0003-3238-2982; OpenAlex author ID A5103218426. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 4
- Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients. Last author DOI 10.1038/s41401-024-01403-8↗
- Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.lfs.2020.118302↗
- Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and Anticipation of Human Efficacious Doses. Last author DOI 10.1016/j.xphs.2019.10.035↗
- N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation. Last author DOI 10.1016/j.taap.2019.114789↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Qingyu Yao · 4 shared papers, 2019–2025 · strength 0.55
- Paper Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients. DOI 10.1038/s41401-024-01403-8↗
- Paper Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and… DOI 10.1016/j.xphs.2019.10.035↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Junsheng Xue · 3 shared papers, 2019–2025 · strength 0.44
- Paper Longitudinal and time-to-event modeling for the survival of advanced pancreatic ductal adenocarcinoma patients. DOI 10.1038/s41401-024-01403-8↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Ye Yao · 3 shared papers, 2019–2020 · strength 0.30
- Paper Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and… DOI 10.1016/j.xphs.2019.10.035↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Chunyi Hao · 3 shared papers, 2019–2020 · strength 0.30
- Paper Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and… DOI 10.1016/j.xphs.2019.10.035↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Hong Su · 3 shared papers, 2019–2020 · strength 0.30
- Paper Pharmacokinetic/Pharmacodynamic Modeling of the Anti-Cancer Effect of Dexamethasone in Pancreatic Cancer Xenografts and… DOI 10.1016/j.xphs.2019.10.035↗
- Paper Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocar… DOI 10.1016/j.lfs.2020.118302↗
- Paper N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1… DOI 10.1016/j.taap.2019.114789↗
- Jun Zhou · 1 shared paper, 2025 · strength 0.26
- Can Cui · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.